Symbiotec Pharmalab
add_icon

Symbiotec Pharmalab

1,198.00
+21.25
(1.81%)
Market Cap
7,697.88 Cr
PE Ratio
68.77
Volume
37,13,662.00
Day High - Low
1,246.00 - 1,161.10
52W High-Low
1,196.80 - 934.20
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
7,697.88 Cr
EPS
19.10
PE Ratio
68.77
PB Ratio
5.81
Book Value
202.32
EBITDA
241.00
Dividend Yield
0.00 %
Industry
-
Sector
-
Return on Equity
9.56
Debt to Equity
0.48
Forecast For
Actual

Company News

View All News
Caret
positive
Knovea signs US sales deal for dual chamber vial products3 days ago
Symbiotec Pharmalab's subsidiary Knovea has partnered with a major global pharma company for US sales of two dual chamber vial products.
positive
Symbiotec Pharmalab gets VAI status from U.S. FDA4 days ago
Symbiotec Pharmalab received the U.S. FDA Establishment Inspection Report for its Pithampur, Madhya Pradesh facility with Voluntary Action Indicated (VAI) status.
neutral
Symbiotec Pharmalab Ltd will hold its earnings conference call for the quarter ended June 30, 2026, on September 22, 2026. The event is hosted by JM Financial Institutional Securities Limited.
View more
Growth Rate
Revenue Growth
15.38 %
Net Income Growth
13.42 %
Cash Flow Change
269.42 %
ROE
-19.66 %
ROCE
-3.26 %
EBITDA Margin (Avg.)
1.28 %

Quarterly Financial Results

Quarterly Financials
Jun 2025
Mar 2026
Jun 2026
Revenue
206
245
219
Expenses
145
183
173
EBITDA
61
62
46
Operating Profit %
29 %
25 %
21 %
Depreciation
11
20
22
Interest
5
7
6
Profit Before Tax
45
35
18
Tax
15
8
4
Net Profit
30
28
14
EPS in ₹
5.37
4.78
2.24

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
2026
Total Assets
679
768
815
990
1,295
1,580
1,781
Fixed Assets
230
261
280
299
448
438
1,120
Current Assets
398
423
426
400
508
493
486
Capital Work in Progress
31
28
40
182
208
568
65
Investments
9
5
5
5
4
2
5
Other Assets
408
474
490
504
635
572
592
Total Equity & Liabilities
679
768
815
990
1,295
1,580
1,781
Current Liabilities
256
225
189
228
351
473
528
Non Current Liabilities
26
23
28
141
229
292
104
Total Equity
397
521
599
621
715
815
1,150
Reserve & Surplus
386
510
588
611
704
804
1,137
Share Capital
11
11
11
11
11
11
13

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
2026
Net Cash Flow
-1
1
-5
3
19
-16
Investing Activities
-96
-32
-220
-206
-307
-227
Operating Activities
174
18
69
188
47
175
Financing Activities
-79
15
146
22
278
36

Share Holding

% Holding
Dec 2025
Aug 2026
Promoter
35.07 %
33.28 %
FIIs
0.00 %
21.08 %
DIIs
0.00 %
27.52 %
Government
0.00 %
0.00 %
Public / Retail
0.00 %
16.60 %
Others
64.93 %
1.52 %
No of Share Holders
15
93

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 Sept 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 Sept 2026 1,138.05 1,095.10

Announcements

Symbiotecs Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agreement With A Leading Global Pharmaceutical Company For Dual Chamber Vial Products In The U.S.3 days ago
Closure of Trading Window4 days ago
Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report ("EIR") From U.S. FDA For Its Manufacturing Facility In Pithampur (SEZ) With VAI Classification 4 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeSep 22, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 22, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 21, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationSep 21, 2026
Results - Financials For Quarter Ended Jun 30 2026Sep 21, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Monday September 21 2026Sep 21, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2026
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Sep 12, 2026
Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of Symbiotec Pharmalab Limited (The Company) To Be Held On September 21 2026Sep 11, 2026
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 11, 2026
Update On Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015.Sep 03, 2026
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 02, 2026
Closure of Trading WindowSep 01, 2026
Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015.Sep 01, 2026
Disclosure Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Sep 01, 2026
Listing of Equity Shares of Symbiotec Pharmalab LtdSep 01, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
1.18%
60720
1.18%
1.18%
TRUSTMF Multi Cap Fund Direct-Growth
0.62%
50610
0.62%
0.62%
TRUSTMF Large & Mid Cap Fund Direct-Growth
1.37%
50610
1.37%
1.37%
Groww Small Cap Fund Direct-Growth
0.39%
30360
0.39%
0.39%
Unifi Dynamic Asset Allocation Fund Direct-Growth
0.06%
8342
0.06%
0.06%
Baroda BNP Paribas Services Fund Direct-Growth
0.08%
5216
0.08%
0.08%
Unifi Flexi Cap Fund Direct-Growth
0.04%
1043
0.04%
0.04%
The Wealth Company Flexi Cap Fund Direct-Growth
0.02%
521
0.02%
0.02%
The Wealth Company Multi Asset Allocation Fund Direct-Growth
0.02%
417
0.02%
0.02%
The Wealth Company Large & Mid Cap Fund Direct-Growth
0.01%
157
0.01%
0.01%
The Wealth Company Small Cap Fund Direct-Growth
0.01%
157
0.01%
0.01%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.41%
0
0.00%
0.41%
Mahindra Manulife Small Cap Fund Direct-Growth
0.46%
0
0.00%
0.46%
Baroda BNP Paribas Innovation Fund Direct-Growth
0.03%
0
0.00%
0.03%
Baroda BNP Paribas Large & Mid Cap Fund Direct-Growth
0.03%
0
0.00%
0.03%
Baroda BNP Paribas Large Cap Fund Direct-Growth
0.02%
0
0.00%
0.02%
Baroda BNP Paribas Manufacturing Fund Direct-Growth
0.01%
0
0.00%
0.01%
Baroda BNP Paribas Midcap Fund Direct-Growth
0.01%
0
0.00%
0.01%
Baroda BNP Paribas Multi Asset Fund Direct-Growth
0.03%
0
0.00%
0.03%
Baroda BNP Paribas Retirement Fund Direct-Growth
0.01%
0
0.00%
0.00%
Baroda BNP Paribas Small Cap Fund Direct-Growth
0.01%
0
0.00%
0.01%
Baroda BNP Paribas Value Fund Direct-Growth
0.03%
0
0.00%
0.03%
Edelweiss Aggressive Hybrid Fund Direct-Growth
0.05%
0
0.00%
0.05%
Edelweiss Large Cap Fund Direct-Growth
1.39%
0
0.00%
1.39%
Baroda BNP Paribas Flexi Cap Fund Direct-Growth
0.01%
0
0.00%
0.01%

Technical Indicators

RSI(14)
Neutral
61.59
ATR(14)
Volatile
69.17
STOCH(9,6)
Neutral
49.86
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
0.00
ADX(14)
Weak Trend
0.00
UO(9)
Bullish
0.00
ROC(12)
Uptrend And Accelerating
10.92
WillR(14)
Overbought
-18.43